U.S. Retail Distributors Stock News

Glaukos (GKOS) has drawn fresh attention after reporting fourth quarter and full year 2025 results, issuing 2026 sales guidance of US$600 million to US$620 million, and recording a US$112,867,000 intangible asset impairment. See our latest analysis for Glaukos. Despite the latest guidance and impairment announcement, Glaukos’ recent trading has been weaker, with a 1 month share price return of 11.31% and a 1 year total shareholder return decline of 30.28%. However, the 3 year total...

Despite announcing strong earnings, Vertex, Inc.'s ( NASDAQ:VERX ) stock was sluggish. Our analysis uncovered some...

If you are wondering whether Expand Energy is still worth your attention at around US$102.75, the key question is how that price stacks up against the company’s underlying value. The stock has been relatively steady in the short term, with returns of 0.5% over the last 7 days and 2.9% over the last 30 days, while year to date it is down 6.4% and the 1 year return is a marginal 0.4%, set against a 46.1% 3 year return and a 195.9% 5 year return. Recent news coverage around Expand Energy has...

If you are wondering whether National Fuel Gas is still reasonably priced after its run, this breakdown will help you work out what you are really paying for today. The stock most recently closed at US$87.17, with reported returns of 2.7% over 7 days, 7.3% over 30 days, 6.2% year to date, 22.3% over 1 year, 70.9% over 3 years and 123.3% over 5 years. Recent coverage has focused on how National Fuel Gas fits into the wider US utilities sector and how investors are thinking about regulated...

In February 2026, CBIZ, Inc. announced a new share repurchase program authorizing the buyback of up to 5,000,000 shares through March 31, 2027, funded by operating cash flow and its credit facility following the expiration of its prior plan. This renewed commitment to returning capital highlights management’s confidence in CBIZ’s cash generation and balance sheet flexibility even as it continues to fund growth initiatives. We’ll now examine how this newly authorized, debt-supported...

If you are wondering whether Jabil's current share price reflects its underlying value, this article will walk you through what the numbers actually say. Jabil shares last closed at US$257.40, with returns of a 0.6% decline over 7 days, 2.4% over 30 days, 7.1% year to date, 51.7% over 1 year and a very large gain over 5 years. Recent headlines around Jabil have focused on its position as a key manufacturing partner for large electronics and industrial customers, as well as ongoing portfolio...

Why Banc of California is on investors’ radar today Banc of California (BANC) is drawing attention after recent share price moves, with the stock last closing at $20.10. Investors are weighing this level against the bank’s current earnings profile and valuation signals. See our latest analysis for Banc of California. At the current share price of $20.10, Banc of California’s recent 18.93% 3 month share price return and 29.49% 1 year total shareholder return suggest momentum has improved...

If you are trying to figure out whether Ocular Therapeutix at around US$6.99 still offers value or has run its course, you are in the right place. The stock has recently been volatile, with a 22.6% decline over the last 7 days, a 38.0% decline over 30 days and a 40.9% decline year to date, while the 3 year return sits at 21.8%. Recent headlines around Ocular Therapeutix have focused on its position in ophthalmology and how its pipeline and products could shape future prospects. This helps...

HubSpot, Inc.'s ( NYSE:HUBS ) strong earnings report was rewarded with a positive stock price move. We did some digging...

Anterix Inc.'s ( NASDAQ:ATEX ) stock performed strongly after the recent earnings report. However, we think that...

In the last year, multiple insiders have substantially increased their holdings of aTyr Pharma, Inc. ( NASDAQ:ATYR...

Q2 Holdings, Inc.'s ( NYSE:QTWO ) earnings announcement last week was disappointing for investors, despite the decent...

Some Yum China Holdings, Inc. ( NYSE:YUMC ) shareholders may be a little concerned to see that the CEO & Executive...

Some TTM Technologies, Inc. ( NASDAQ:TTMI ) shareholders may be a little concerned to see that the Director, Thomas...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

AtriCure, Inc. recently reported its fourth quarter and full-year 2025 results, with quarterly revenue of US$140.5 million, a swing to net income of US$1.76 million, and substantially reduced full-year losses alongside 2025 revenue of US$534.53 million. Management also issued 2026 guidance calling for US$600 million to US$610 million in revenue and positive net income, while highlighting progress in key clinical programs and new product launches that could influence the company’s market...

If you are wondering whether Innodata's recent share price pulls you toward a bargain or a value trap, this article will walk through what the current market price might be saying about the stock. The share price closed at US$43.02, with returns of a 9.5% decline over 7 days, a 30.1% decline over 30 days and an 18.8% decline year to date. Over the past 3 years and 5 years, the returns are very large compared to the starting point. Over the past year, Innodata has also recorded a 25.9%...

Corteva (CTVA) is drawing fresh attention after leading Resurrect Bio’s US$8.1 million Series A round through its Corteva Catalyst platform. The move is aimed at supporting new crop protection traits and potential commercial partnerships. See our latest analysis for Corteva. Alongside the Resurrect Bio investment and a recently completed US$569.98 million share buyback, Corteva’s 30 day share price return of 8.49% and 90 day share price return of 16.81% suggest momentum has been building,...

Kinsale Capital Group, Inc. recently reported past fourth quarter and full-year 2025 results, with revenue rising to US$483.27 million and US$1.87 billion respectively, alongside higher net income and earnings per share year over year. The company’s strong profitability was accompanied by a new US$0.25 per-share dividend declaration and a board transition that reduces the director count from ten to nine without reported governance disputes. We’ll now explore how Kinsale’s stronger earnings...

Wondering whether Affirm Holdings at around US$51.60 still lines up with the story you have in mind, or if the current price is getting ahead of itself or lagging behind the fundamentals. The stock has recently been volatile, with a 13.5% decline over the last 7 days, a 31.0% decline over the last 30 days, and a 30.3% decline year to date, even though the 3 year return is very large at about 3x and the 1 year return sits at a 36.3% decline. Recent headlines around Affirm have focused on its...

Why recent analyst upgrades are putting BorgWarner (BWA) on investors’ radar Recent analyst upgrades for BorgWarner (BWA), backed by fresh supply deals in electric and hybrid systems, have pushed the stock into focus for investors watching the auto parts shift toward electrified powertrains. See our latest analysis for BorgWarner. BorgWarner’s recent contracts in hybrid and electric systems, a fresh Master Supply Agreement for turbine generators tied to AI data centers, an active buyback...

In the fourth quarter, Impala Asset Management exited its entire position in Academy Sports and Outdoors, selling 397,115 shares for about US$19.86 million, after the retailer reported third-quarter net sales of US$1.38 billion, a 3% increase, and diluted EPS of US$1.05, up 14% with stronger margins. This complete fund exit, despite quarterly profit growth but year-to-date net income falling 14.6% and comparable sales still negative, highlights investor concern about the durability of...

If you are wondering whether Becton Dickinson is attractively priced right now, the recent share performance and our valuation checks give you a lot to work with before you make up your mind. The stock last closed at US$177.38, with a 3.3% gain over 7 days, a 14.4% decline over 30 days, and returns of 2.4% over 1 year, 1.3% over 5 years, and a 9.0% decline year to date. Recent news about Becton Dickinson has focused on its position as a large medical technology company and how it fits into...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) reports its first full year of profitability, supported by its TTR franchise. The company introduces a new RNAi manufacturing platform aimed at supporting its growing portfolio of RNA targeted medicines. Alnylam enters new industry partnerships that expand its presence across RNA therapeutics and drug discovery. For investors watching RNA based medicines, Alnylam sits at the center of a maturing part of biotech with an approved TTR franchise and a...